Glycomine

Glycomine is a private, pre-revenue biotech advancing a novel substrate replacement platform for rare diseases. Its lead program, GLM101, is in a global Phase 2b trial for PMM2-CDG, representing the first potential disease-modifying therapy for this severe condition. The company is well-capitalized following a $115M Series C financing in April 2025, which is funding the pivotal-stage development of GLM101. Glycomine's approach aims to bypass genetic deficiencies by delivering missing substrates or enzymes, with potential application across a range of rare metabolic disorders.

Substrate replacement therapy platform designed to deliver missing substrates, enzymes, or proteins to bypass genetic deficiencies and restore function in rare metabolic diseases.

For PMM2-CDG, there are currently no approved disease-modifying therapies, making GLM101 a first-in-class candidate. Competition may arise from other investigational approaches (e.g., gene therapy, enzyme replacement) but appears limited at present. The broader rare disease space is highly competitive for funding and platform validation.